NCT02413736 2025-03-12
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Helsinki University Central Hospital
Phase 3 Active not recruiting
Clinical Trials
19 trialsNCT02260505 2024-01-05
ImadGist
Centre Leon Berard
Phase 3 Completed
NCT05970900 2023-08-01
PIRKER
Fujian Medical University Union Hospital
Phase 3 Not yet recruiting
NCT00812240 2023-02-01
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
AB Science
Phase 3 Terminated
NCT01151852 2020-01-14
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
Phase 3 Completed
NCT00103168 2018-07-09
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00324987 2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00785785 2016-06-16
ENESTg1
Novartis
Phase 3 Completed
NCT02576080 2015-10-15
GIGIST
Assistance Publique Hopitaux De Marseille
Phase 3 Unknown
NCT00293124 2015-08-13
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
Central European Cooperative Oncology Group
Phase 3 Completed
NCT00009906 2014-12-23
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00685828 2014-07-04
Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Unknown
NCT00751036 2014-03-26
MACS0375
Novartis
Phase 3 Terminated
NCT01031628 2013-09-09
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Sarcoma Alliance for Research through Collaboration
Phase 3 Terminated
NCT00041197 2013-07-16
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00956072 2012-09-24
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed
NCT00116935 2011-12-30
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Scandinavian Sarcoma Group
Phase 3 Completed
NCT00372567 2011-03-17
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Pfizer
Phase 3 Terminated